glp-1 kidney outcomes news

glp-1 kidney outcomes news function loss and albuminuria progression with receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence | Cardiovascular Diabetology Effects of GLP-1 receptor agonists

Name: glp-1 kidney outcomes news function loss and albuminuria progression with receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence | Cardiovascular Diabetology Effects of GLP-1 receptor agonists
Brand: actil.am
SKU: 72224474129
Price: 27.40 USD
Availability: InStock
Rating: 4.6588 (14 reviews)

SKU: 72224474129

4.7

USD27.40 USD49.40

Pay in 4 interest-free payments of $6.85 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 15 - Aug 20

Description

-Promotes the transport and burning of fatty acids

hypertension, type 2 DM, dyslipidemia) A meta-analysis of 22 trials involving over 17,000 patients determined that 50.2% and 17.5% of patients treated with GLP-1RAs (exenatide, semaglutide & liraglutide) experienced a weight loss of 5% and 10% compared to placebo, and that patients without type 2 diabetes achieved a significantly greater weight loss compared to those with diabetes (Vosoughi et al, 2022)

Estimated delivery: approximately 2 weeks